Printer Friendly

PERSEPTIVE BIOSYSTEMS ANNOUNCES AWARD OF PATENT FOR IMMUNOASSAY TECHNOLOGY; FIRST IMMUNODETECTION PATENT TO ISSUE

 CAMBRIDGE, Mass., Aug. 17 /PRNewswire/ -- PerSeptive Biosystems, Inc., (NASDAQ: PBIO) today announced that the U.S. Patent and Trademark Office has issued to the company U.S. Patent No. 5,234,586 for On-line Product Identification in a Chromatography Effluent by Subtraction. Using this technique, biopharmaceutical developers and manufacturers can continuously track proteins peptides, oligonucleotides, or other materials to which a binding protein can be made during the production process.
 Subtractive Immunoassays, embodied in PerSeptive's Real Time Process Monitor (RPM)(TM) instrument can revolutionize the development and production of biopharmaceuticals by making available the monitoring tools essential for efficient and consistent production processes. Previously, manufacturers had to collect product samples at each of the multiple steps in drug production, then wait for analytical laboratory results before continuing the process. On-line, real-time monitoring afforded by Subtractive ID(TM) Assays and the RPM achieve the instant feedback required for cost-effective development and monitoring of pharmaceutical production processes.
 Noubar B. Afeyan, Ph.D., PerSeptive's president and CEO commented: "We are extremely pleased to receive official recognition of the novel nature of the tools that PerSeptive has invented, developed, and commercialized. This patent, along with increasing industry acceptance of our materials and instrumentation, affirm that our br technologies can transform the development and manufacture of biopharmaceuticals."
 With Subtractive Immunoassay technology, biopharmaceutical manufacturers can perform real-time assays during manufacturing and production process by sampling a small process stream and passing it through an ID Sensor Cartridge on PerSeptive's Real-Time Process Monitor(RPM)(TM) instrument or PerSeptive's new Integral(TM) Micro- analytical workstation. The RPM passes on sample of the process stream through the ID cartridge derivitized with an antibody to the product, and a second sample through the instrument's detection system only. The concentration and purity of the desired molecule in the stream cartridge is then calculated by the instrument's software. Since ID cartridges can be used at very high flow rates, an assay can be performed every 15- 20 seconds, ensuring constant production stream monitoring. RPM software tallies accumulated bound antigen and initiates an evaluation or regeneration cycle as required during the production process.
 PerSeptive's 586 patent is the first to issue of a series of five U.S. patent applications based on its ImmunoDetection(TM) technology. ImmunoDetection assays rely on patented perfusive media, using these media with antibodies immobilized on solid surfaces. Conventionally, immunoassays are carried out with antibodies immobilized on surfaces such as multi-well plastic dishes, and require hours to days to perform, since incubations are time consuming due to the limited amount of antibody immobilized on the solid surface of these dishes.
 Conversely, the speed of perfusive immunoassays result from the large accessible surface area of the perfusive media, and the ability to concentrate antigen with antibody incubation in the pore spaces of the media. As a result, the amount of antigen present in the pores is typically far less than the amount of immobilized antibody, thus greatly accelerating the process of antibody-antigen binding. ImmunoDetection also exploits the automation characteristic of current chromatography instrumentation, dramatically improving the precision of immunoassays in the perfusion mode.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography (R) for high resolution separations of biomolecules ten to one thousand times faste than conventional chromatography, ImmunoDetection(TM) for real-time immunoassays in a flow-through cartridge format, and Rational Surface Design(TM), synthetic surfaces that bind biomolecules with the high specificity of antibodies.
 -0- 8/17/93
 /CONTACT: Noubar B. Afeyan, president and CEO, (scientific); Patricia F. Dimond, Ph.D., director, corporate development, (investor) both of PerSeptive Biosystems, Inc., 617-621-1787/
 (PBIO)


CO: PerSeptive Biosystems, Inc. ST: Massachusetts IN: MTC SU:

DJ -- NE003 -- 3390 08/17/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 17, 1993
Words:660
Previous Article:SYMBOL TECHNOLOGIES OFFERS BAR CODE-BASED SOLUTIONS FOR COMPUTERS ASSOCIATES CA-CAS MANUFACTURING SYSTEM
Next Article:GTECH ACQUIRES BENEFITS DELIVERY SYSTEMS BUSINESS FROM GENERAL INSTRUMENT CORPORATION
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters